title: The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes.
abstract: Here we report on the anti-tumor effects of five interferon (IFN)-alpha subtypes, alpha1, alpha2, alpha5, alpha8, and alpha10 in chronic myelogenous leukaemia (CML)-derived cell lines. All of the CML cells can respond to IFN-alpha although the anti-tumor effects of IFN-alpha depend on the target cell and on the type of IFN-alpha subtype used. Proliferation assays showed that IFN-alpha8 was substantially more effective than the other four IFN-alpha subtypes. IFN-alpha8 was the most potent at upregulating immunomodulatory molecule expression while IFN-alpha1 was least potent. These data indicate in vitro distinctions between IFN-alpha subtypes that should be appreciated more in the clinic.
authors.affiliation: Fujisaki Institute, Hayashibara Biochemical Laboratories, Inc., 675-1 Fujisaki, Okayama 702-8006, Japan. fujisaki@hayashibara.co.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yanai
authors.forename: Osamu
authors.initials: O
authors.lastname: Sanou
authors.forename: Kouzou
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamauchi
authors.forename: Hakuo
authors.initials: H
authors.lastname: Ikegami
authors.forename: Masashi
authors.initials: M
authors.lastname: Kurimoto
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D053222:Fas Ligand Protein; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D005805:Genes, MHC Class I; D006680:HLA Antigens / Q000096:biosynthesis; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007370:Interferon Type I / Q000494:pharmacology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000145:classification / Q000494:pharmacology*; D007372:Interferons / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D020298:U937 Cells / Q000187:drug effects / Q000378:metabolism; D019014:fas Receptor / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D006680:HLA Antigens; C469326:IFNA10 protein, human; C554164:IFNA8 protein, human; D007155:Immunologic Factors; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D019014:fas Receptor; D007372:Interferons